Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €126.33 EUR
Change Today -1.20 / -0.94%
Volume 0.0
SIQ On Other Exchanges
As of 10:15 AM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

sigma-aldrich (SIQ) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/13/15 - €131.55
52 Week Low
05/29/14 - €72.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SIGMA-ALDRICH (SIQ)

sigma-aldrich (SIQ) Related Businessweek News

No Related Businessweek News Found

sigma-aldrich (SIQ) Details

Sigma-Aldrich Corporation, a life science and high technology company, develops, manufactures, purchases, and distributes various chemicals, biochemicals, and equipment products worldwide. The company provides chemical products, reagents, and kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, and diagnosis of disease; and as key components in pharmaceutical, diagnostics, and high technology manufacturing. It offers media and critical raw materials for industrial cell culture, contract manufacturing services, pharmaceutical safety testing services, and organometallic precursors for semiconductor manufacturing. The company sells its products to pharmaceutical companies, universities, commercial laboratories, industrial companies, biotechnology companies, non-profit organizations, governmental institutions, diagnostic, chemical and electronics companies, and hospitals. Sigma-Aldrich Corporation was founded in 1951 and is based in St. Louis, Missouri.

9,400 Employees
Last Reported Date: 05/7/15
Founded in 1951

sigma-aldrich (SIQ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.0M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $485.4K
Executive Vice President and President of App...
Total Annual Compensation: $455.7K
Executive Vice President and President of SAF...
Total Annual Compensation: $404.2K
Compensation as of Fiscal Year 2014.

sigma-aldrich (SIQ) Key Developments

SAFC Commercial Expands Manufacturing Facility in St. Louis

Sigma-Aldrich Corp. reported its SAFC Commercial has expanded its St. Louis facility to support commercial-scale manufacturing of antibody drug conjugate, or ADC. In Sigma's announcement of the expansion, the life sciences company said the expansion would come online in the third quarter of 2015 and allow its customers to work with a single supplier from discovery through commercialization. Sigma said the expansion was designed to safely handle highly active compounds, and meet with consulting company SafeBridge's "category 4" designation.

Sigma-Aldrich Corporation's SAFC Commercial Completes ADC Commercial Manufacturing Capacity Expansion in St. Louis

Sigma-Aldrich Corporation announced that SAFC Commercial, its custom manufacturing services business unit, has completed the expansion of its St. Louis facility to support commercial-scale antibody drug conjugate (ADC) manufacturing. The facility is in final validation and expected to go online as planned in the third quarter of 2015. Once validated, customers will benefit from working with a single supplier from discovery to commercialization. Designed to meet SafeBridge® category 4 compound handling to safely accommodate usage of highly-active compounds, the St. Louis expansion creates commercial-scale manufacturing capacity for ADCs and other targeted therapies. The expanded capabilities in St. Louis are further enhanced by expanded commercial capacity for highly-active manufacturing and storage at the company's Madison, Wis. facility.

Sigma-Aldrich Corporation's SAFC Commercial Expands Carlsbad, Calif. Facility to Support Commercial-Scale Gene Therapy Production, Testing and Filling

Sigma-Aldrich Corporation's SAFC Commercial announced the strategic expansion of its existing facility in Carlsbad, Calif. The investment will further enable SAFC to offer clinical and commercial bulk drug production, as well as fill/finish of viral products for its gene therapy, viral vaccine and immunotherapy customers. The expanded Carlsbad facility complements a global footprint of GMP services in the virus and gene therapy segment, including cell banking in Rockville, Md., and manufacturing in the Glasgow location in Scotland, U.K. The investment was driven by continued interest in targeted gene therapies for indications such as hemophilia and cancer immunotherapies (CAR-T cells). Utilizing the biosafety testing expertise of BioReliance, the Carlsbad facility provides a full range of GMP manufacturing and testing services to its customers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SIQ:GR €126.33 EUR -1.20

SIQ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CR Bard Inc $169.73 USD -0.97
Dr Reddy's Laboratories Ltd 3,535 INR +7.30
International Flavors & Fragrances Inc $119.10 USD -0.17
UCB SA €65.39 EUR +0.75
Waters Corp $133.42 USD -1.16
View Industry Companies

Industry Analysis


Industry Average

Valuation SIQ Industry Range
Price/Earnings 33.5x
Price/Sales 6.0x
Price/Book 5.3x
Price/Cash Flow 33.3x
TEV/Sales 5.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SIGMA-ALDRICH, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at